{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:49:08Z","timestamp":1787856548228,"version":"build-2784847793"},"reference-count":27,"publisher":"European Respiratory Society (ERS)","issue":"6","funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["G0800649"],"award-info":[{"award-number":["G0800649"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2018,10,5]]},"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:p>Previous publications have highlighted the disparity between research trial populations and those in clinical practice, but it has not been established how this relates to randomised controlled trials (RCTs) of phenotype-targeted biological therapies in severe asthma.<\/jats:p><jats:p>Detailed characterisation data for 342 severe asthma patients within the Wessex Severe Asthma Cohort (WSAC) was compared against comprehensive trial eligibility criteria for published phase IIB and phase III RCTs evaluating biological therapies in severe asthma since 2000.<\/jats:p><jats:p>37 RCTs evaluating 20 biological therapies were identified. Only a median of 9.8% (range 3.5\u201317.5%) of severe asthma patients were found to be eligible for enrolment in the phase III trials. Stipulations for airflow obstruction, bronchodilator reversibility and smoking history excluded significant numbers of patients. A median of 78.9% (range 73.2\u201386.6%) of patients with severe eosinophilic asthma would have been excluded from participation in the phase III licensing trials of interleukin (IL)-5\/IL-5R targeted therapies.<\/jats:p><jats:p>Despite including only well characterised and optimally treated severe asthmatics under specialist care within the WSAC study, the vast majority were excluded from trial participation by criteria designed to re-confirm diagnostic labels rather than by biomarker criteria that predict the characteristic addressed by the treatment.<\/jats:p>","DOI":"10.1183\/13993003.01444-2018","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T17:26:03Z","timestamp":1540488363000},"page":"1801444","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":103,"title":["Randomised controlled trials in severe asthma: selection by phenotype or stereotype"],"prefix":"10.1183","volume":"52","author":[{"given":"Thomas","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6324-7540","authenticated-orcid":false,"given":"Thomas","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5022-4550","authenticated-orcid":false,"given":"Kerry","family":"Gove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clair","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"key":"2024102100400152000_52.6.1801444.1","unstructured":"Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. Geneva, World Health Organisation, 2007. www.who.int\/gard\/publications\/GARD%20Book%202007.pdf"},{"key":"2024102100400152000_52.6.1801444.2","doi-asserted-by":"publisher","DOI":"10.1186\/s40733-016-0029-3"},{"key":"2024102100400152000_52.6.1801444.3","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2024102100400152000_52.6.1801444.4","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-204114"},{"key":"2024102100400152000_52.6.1801444.5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaci.2015.11.020","article-title":"Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1","volume":"138","author":"Hinks","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2024102100400152000_52.6.1801444.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200906-0896OC"},{"key":"2024102100400152000_52.6.1801444.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00779-2015"},{"key":"2024102100400152000_52.6.1801444.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69290-8"},{"key":"2024102100400152000_52.6.1801444.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.11.037"},{"key":"2024102100400152000_52.6.1801444.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.12.1871"},{"key":"2024102100400152000_52.6.1801444.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30879-6"},{"key":"2024102100400152000_52.6.1801444.12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01359-2015"},{"key":"2024102100400152000_52.6.1801444.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2004.03.026"},{"key":"2024102100400152000_52.6.1801444.14","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.066837"},{"key":"2024102100400152000_52.6.1801444.15","unstructured":"Global strategy for asthma management and prevention (2017 update). Global Initiative for Asthma 2017. https:\/\/ginasthma.org\/wp-content\/uploads\/2016\/01\/wms-GINA-2017-main-report-tracked-changes-for-archive.pdf"},{"key":"2024102100400152000_52.6.1801444.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.11.639"},{"key":"2024102100400152000_52.6.1801444.17","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00261903"},{"key":"2024102100400152000_52.6.1801444.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.10.007"},{"key":"2024102100400152000_52.6.1801444.19","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.137414"},{"key":"2024102100400152000_52.6.1801444.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.12.1574"},{"key":"2024102100400152000_52.6.1801444.21","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200304-503OC"},{"key":"2024102100400152000_52.6.1801444.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810223391703"},{"key":"2024102100400152000_52.6.1801444.23","unstructured":"Guideline on the clinical investigation of medicinal products for the treatment of asthma. London, European Medicines Agency, 2015. www.ema.europa.eu\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-asthma_en.pdf Date last updated: October 22, 2015."},{"key":"2024102100400152000_52.6.1801444.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011857"},{"key":"2024102100400152000_52.6.1801444.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.06.014"},{"key":"2024102100400152000_52.6.1801444.26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chest.2016.09.035","article-title":"Omalizumab treatment response in a population with severe allergic asthma and overlapping COPD","volume":"151","author":"Maltby","year":"2017","journal-title":"Chest"},{"key":"2024102100400152000_52.6.1801444.27","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/S0140-6736(17)32397-8","article-title":"Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial","volume":"390","author":"Woodcock","year":"2017","journal-title":"Lancet"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01444-2018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:00:35Z","timestamp":1740380435000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01444-2018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,25]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,12,13]]},"published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1183\/13993003.01444-2018"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01444-2018","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,25]]}}}